AUPH
NASDAQAurinia Pharmaceuticals Inc
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Website
News25/Ratings12
News · 26 weeks39-58%
2025-10-262026-04-19
Mix2690d
- Insider14(54%)
- SEC Filings5(19%)
- Other5(19%)
- Earnings2(8%)
Latest news
25 items- SECSEC Form DEF 14A filed by Aurinia Pharmaceuticals IncDEF 14A - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- SECAurinia Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- INSIDERSEC Form 3 filed by new insider Cole Ryan3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hearne Michael S3 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- PRAurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value RightAurinia Pharmaceuticals Inc. (NASDAQ:AUPH), a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced today it has entered into a definitive merger agreement (the "Merger Agreement") to acquire Kezar Life Sciences, Inc. (NASDAQ:KZR), a biotechnology company focusing on small-molecule therapeutics to treat unmet needs in autoimmunity and cancer, for $6.955 in cash per share of Kezar common stock, plus one non-transferable contingent value right ("CVR"), which represents the right to receive: (i) potential payments relating to the ongoing clinical development or disposition of zetomipzomib; (ii) certain proce
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aurinia Pharmaceuticals IncSCHEDULE 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
- PRMKT Capital Applauds Aurinia Pharmaceuticals' Management TransitionBelieves the Board's Decision to Remove CEO Peter Greenleaf and Install Kevin Tang as CEO Validates Multi-Year Shareholder Campaign Commends New Leadership's Commitment to Shareholder Alignment Through Zero CEO Compensation Expects Aurinia to Enter New Chapter of Disciplined Capital Allocation and Value Creation MKT Capital Ltd. (together with its affiliates, "MKT Capital" or "we"), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) ("Aurinia" or the "Company"), today issued the following statement in response to the Company's announcement that Kevin Tang has been appointed Chief Executive Officer, effective immediately. Antoine Khalife, Founder of MKT
- SECAurinia Pharmaceuticals Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- PRAurinia Announces Management TransitionAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced today that Kevin Tang, Aurinia's Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant to facilitate the transition. "Aurinia thanks Peter for his many contributions to the Company over his 7-year tenure and wishes him the best in his future endeavors," stated Mr. Tang. "Aurinia today is in an extremely strong position in no small part due to Peter's stewardship. LUPKYNIS is emerging as a standard therapy for lupus nephritis, and our lead pipeline product, aritinercept, is advancing quickly through clinical studies. I look forward to working closely with the Aurinia team on our
- INSIDERSVP, Chief Medical Officer Keenan Greg covered exercise/tax liability with 8,069 shares, decreasing direct ownership by 5% to 154,449 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERDirector Tang Kevin bought $12,688,806 worth of shares (900,000 units at $14.10) (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aurinia Pharmaceuticals IncSCHEDULE 13D/A - Aurinia Pharmaceuticals Inc. (0001600620) (Subject)
- INSIDERChief Operating Officer Donley Matthew Maxwell covered exercise/tax liability with 40,761 shares and was granted 58,160 shares, increasing direct ownership by 3% to 680,299 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDEREVP, General Counsel Robertson Stephen P. was granted 59,090 shares and covered exercise/tax liability with 36,525 shares, increasing direct ownership by 5% to 505,861 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERSVP, Chief Medical Officer Keenan Greg was granted 40,586 shares, increasing direct ownership by 33% to 162,518 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERChief Financial Officer Miller Joseph M was granted 57,229 shares and covered exercise/tax liability with 37,511 shares, increasing direct ownership by 4% to 576,421 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERChief Executive Officer Greenleaf Peter was granted 196,403 shares and covered exercise/tax liability with 100,890 shares, increasing direct ownership by 5% to 1,840,379 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- SECSEC Form 10-K filed by Aurinia Pharmaceuticals Inc10-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- SECAurinia Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aurinia Pharmaceuticals Inc. (0001600620) (Filer)
- PRAurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business ProgressFull Year 2025 LUPKYNIS Sales Grew 25% Announces LUPKYNIS Sales Guidance for 2026 of $305 Million to $315 Million Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided an update on recent business progress. Financial Results Total Revenue: For the three and twelve months ended December 31, 2025, total revenue was $77.1 million and $283.1 million, up 29% and 20%, respectively, compared to $59.9 million and $235.1 million, respectively, for the same periods of 2024. Net Product Sales: For the three and twelve months ended December 31, 2025, net product sales of LUPKYNIS, the first FDA-approv
- INSIDERChief Operating Officer Donley Matthew Maxwell covered exercise/tax liability with 32,901 shares, decreasing direct ownership by 5% to 662,900 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERChief Executive Officer Greenleaf Peter covered exercise/tax liability with 100,171 shares, decreasing direct ownership by 5% to 1,744,866 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDERChief Financial Officer Miller Joseph M covered exercise/tax liability with 32,424 shares, decreasing direct ownership by 6% to 556,703 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- INSIDEREVP, General Counsel Robertson Stephen P. covered exercise/tax liability with 34,638 shares, decreasing direct ownership by 7% to 483,296 units (SEC Form 4)4 - Aurinia Pharmaceuticals Inc. (0001600620) (Issuer)
- PRAurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026. Aurinia's management team will host a webcast and conference call on February 26, 2026, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-8029 / +1 201-689-8029. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Com